Comparison
Argireline vs. Matrixyl
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Cosmetic
CAS no.
616204-22-9
214047-00-4
Molecular weight
888.99 g/mol
802.06 g/mol
Half-life
no data
no data
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2Palmitoyl-Lys-Thr-Thr-Lys-SerMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Argireline and Matrixyl?
- Argireline is classified as "Cosmetic", while Matrixyl is classified as "Cosmetic". Argireline: Synthetic hexapeptide marketed as a topical anti-wrinkle ingredient (e.g. by Lipotec/Lubrizol). Mechanism modelled on the SNAP-25-blocking action of botulinum toxin, but with substantially lower potency and without intramuscular effect. EU-compliant as a cosmetic ingredient (CosIng), not approved as a medicine. Matrixyl: Synthetic pentapeptide (KTTKS) with a palmitoyl modification, marketed as a topical anti-aging ingredient (Lipotec/Sederma). Structurally derived from a collagen-I fragment; intended to stimulate fibroblast activity. Cosmetic ingredient, not a medicine. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Argireline or Matrixyl?
- The highest available evidence level is "Human trial" for Argireline and "Human RCT" for Matrixyl. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Argireline and Matrixyl in Germany and the United States?
- Germany: Argireline — Unapproved, Matrixyl — Unapproved. United States: Argireline — Unapproved, Matrixyl — Unapproved. These are factual summaries with source and review date on the individual pages.